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Abstract
The Bcl-2 family of proteins plays a pivotal role in regulating cell life and death. Many of these proteins reside in the outer
mitochondrial membrane, oriented towards the cytosol. Cytoprotective Bcl-2 family proteins such as Bcl-2 and Bcl-XL
prevent mitochondrial permeability transition pore opening and release of apoptogenic proteins from mitochondria under
many circumstances that would otherwise result in either apoptosis or necrosis. In contrast, some pro-apoptotic members of
this family such as Bax can induce these destructive changes in mitochondria in both mammalian cells and when expressed
exogenously in yeast. The mechanisms by which Bcl-2 family proteins control cell life and death remain elusive, but may
include both the ability to form ion channels or pores in membranes and physical interactions with a variety of proteins
implicated in apoptosis regulation. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ever since the discovery that the Bcl-2 protein re-
sides in mitochondrial membranes, the worlds of mi-
tochondrial physiology and apoptosis have been in-
extricably linked [1]. The Bcl-2 family consists of
both cell death promoters and cell death preventers.
Mammalian species appear to contain at least 14
members, including the anti-apoptotic proteins Bcl-
2, Bcl-XL, Mcl-1, A1/B£-1, and Bcl-W [2^7], and the
pro-apoptotic members Bax, Bcl-XS, Bak, Bad, Bik,
Bim, Bid, Hrk, and Bok [3,8^17]. Homologs have
also been found in avian species [18,19] and frogs
[20], as well as some lower organisms (invertebrates),
such as the anti-apoptotic protein CED-9 of Caeno-
rhabditis elegans [21]. Several human herpesviruses
also encode homologs of Bcl-2, including BHRF-1
in Epstein^Barr virus [22,23], ORF16 in herpesvirus
Saimiri [24,25] and Kbcl-2 within the Kaposi sarco-
ma-associated virus, human herpesvirus-8 (HHV8)
[26,27]. The African swine fever virus gene 5HL is
also a Bcl-2 homolog [28]. In addition, the adenovi-
rus E1b-19kDa protein serves as a functional homo-
log of Bcl-2, though sharing little amino acid se-
quence identity with it [29]. Many of the Bcl-2
family proteins can interact with each other, forming
a complex network of homo- and heterodimers
[8,30]. The relative ratios of anti-apoptotic and pro-
apoptotic Bcl-2 family proteins play a major role in
determining the ultimate sensitivity or resistance of
cells to myriad stimuli and insults that induce apop-
tosis (reviewed in [31]).
Bcl-2 was ¢rst reported to be an inner mitochon-
drial membrane protein [1], but subsequent studies
suggested an outer membrane location instead [32^
36]. For example, during in vitro import studies, in
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vitro translated Bcl-2 appears to insert into the outer
membrane due to a stretch of hydrophobic amino
acids located at its carboxyl terminus but remains
susceptible to proteolytic degradation unlike intra-
mitochondria proteins. Immunoelectron microscopy
studies have also provided evidence of a primarily
outer membrane location. Interestingly, however,
Bcl-2 appears to be enriched at the contact sites
were the inner and outer membranes come into close
apposition [33], suggesting a potential explanation
for the association of some of the protein with mito-
plasts which have been stripped of their outer mem-
brane using digitonin [1].
Detailed knowledge about the locations of other
Bcl-2 family proteins within mitochondrial mem-
branes is relatively scant, but many members of the
family do indeed appear to be associated with mito-
chondria. Interestingly, the association of some Bcl-2
family proteins with mitochondrial membranes ap-
pears to be inducible rather than constitutive. For
example, typically about half the Bax protein found
in cells resides in the cytosol until an apoptotic signal
is delivered which causes its insertion into mitochon-
drial membranes [37,38]. The mechanisms responsi-
ble for this inducible association of Bax with mito-
chondria remain to be clari¢ed, particularly since
(similar to Bcl-2) it contains a hydrophobic domain
at its carboxyl end that theoretically ought to target
it constitutively into membranes. Not all Bcl-2 family
proteins contain a membrane-anchoring domain near
their carboxyl termini; however, most nevertheless
associate with intracellular membranes perhaps via
dimerization with other members of the family that
are integral membrane proteins.
2. Mitochondrial functions regulated by Bcl-2 family
proteins
Bcl-2 family proteins have been implicated in the
regulation of two important aspects of mitochondria
pathophysiology: (a) mitochondrial permeability
transition (PT) pore opening; and (b) release of
apoptogenic proteins from mitochondria into the cy-
tosol. During apoptosis induced by myriad insults
and stimuli, the electrochemical gradient (v8) across
the inner mitochondrial membrane becomes dissi-
pated (reviewed in [39]). This loss of v8 has been
attributed to the opening of a large conductance in-
ner membrane channel commonly referred to as the
mitochondrial PT pore. Though the structure and
biochemical composition of the PT pore remain
poorly de¢ned, its constituents are thought to include
both inner membrane proteins such as the adenine
nucleotide translocator (ANT) and outer membrane
proteins such as porin (voltage dependent anion
channel) which operate in concert, presumably at
inner and outer membrane contact sites, to create a
channel with approx. 1.5 kDa diameter (reviewed in
[40]). The opening of this non-selective channel in the
inner membrane allows for an equilibration of ions
within the matrix and intermembrane space of mito-
chondria, thus dissipating the electrochemical gra-
dient and uncoupling the respiratory chain.
Several potentially lethal events follow from mito-
chondrial PT pore opening. For example, electrons
that normally would ¢nd their way through the res-
piratory chain to molecular oxygen are instead
shunted into free-radical production. Mitochondrial
ATP production also grinds to a halt, but presum-
ably adequate intracellular stores typically persist
since ATP depletion is not a general feature of apop-
tosis and indeed would usually preclude it. In addi-
tion, the volume dysregulation that occurs upon PT
pore opening leads to entry of water into the protein-
rich matrix of mitochondria, causing the matrix
space to expand. Since the inner membrane with its
folded cristae possesses a larger surface area than the
outer membrane, this matrix volume expansion can
eventually cause the outer membrane to rupture, re-
leasing proteins located within the intermembrane
space into the cytosol.
Two proteins have been described which can trig-
ger apoptosis when released from mitochondria into
the cytosol: cytochrome c and apoptosis inducing
factor (AIF), a putative protease of 50 kDa [41^
44]. Both cytochrome c and AIF share in common
the ability to activate a group of intracellular cys-
teine proteinases called caspases. The caspases are
the chief e¡ectors of apoptosis (reviewed in [45]).
Caspase activation represents the sine qua non of
apoptosis. These proteins are not degradative pro-
teases, but rather clip speci¢c substrates at aspartic
acid residues which appear within particular se-
quence contexts. Caspases lie in a latent state as in-
active zymogens (pro-enzymes) in essentially all ani-
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mal cells, becoming activated under conditions that
culminate in apoptosis. It is the speci¢c proteolytic
events executed by caspases that account directly or
indirectly for the morphological and biochemical
characteristics of the apoptotic cell.
AIF appears to directly activate certain members
of the caspase family, resulting in proteolytic proc-
essing of their proproteins and production of the
mature enzymes [44]. It has been argued that AIF
itself is possibly an aspartic acid-speci¢c protease,
based on experiments where AIF (which was puri¢ed
to apparent homogeneity from the supernatants of
mitochondria induced to undergo PT) was shown
to cleave in vitro recombinant pro-caspase-3 (which
was produced in bacteria and puri¢ed) through a
mechanism that was suppressible by a peptidyl inhib-
itor of caspase family aspartyl proteases [46]. To
date, however, cDNAs encoding AIF have not
been cloned and thus it remains to be determined
whether this protein shares similarity with caspase
family proteases.
Cytochrome c activates caspases through it e¡ects
on a protein called Apaf-1, apoptosis protease acti-
vating factor-1 [47]. Apaf-1 lies in a latent state in the
cytosol of cells. Upon binding cytochrome c, how-
ever, Apaf-1 becomes competent at binding the pro-
form of a speci¢c caspase, pro-caspase-9, presumably
because of cytochrome c-induced conformational
changes in the Apaf-1 protein [48]. This results in
proteolytic activation of pro-caspase-9, possibly
through an autoprocessing mechanism facilitated by
the binding of the caspase-9 to the Apaf-1/cyto-
chrome c complex. The redox state of cytochrome
c is apparently unimportant for its function as a
co-activator of caspases [49]. However, methylated
cytochrome c from yeast is inactive, implying need
for speci¢c structural features of animal cytochrome
c that allow binding to and activation of Apaf-1.
Heme binding is also critical since apo-cytochrome
c does not trigger caspase activation. The beauty of
this system is that apo-cytochrome c can be pro-
duced in the cytosol by translation from a nuclear
encoded gene and then transported into mitochon-
dria for heme attachment, without killing the cell.
Since cytochrome c is essential for execution of oxi-
dative phosphorylation, cells cannot discard this
molecule and still produce ATP through aerobic res-
piration. This dependence on cytochrome c for res-
piration, therefore, presumably ensures that nearly
all cells retain the cytochrome c-based mechanism
for apoptosis, perhaps explaining in part why all an-
imals cells seem to be capable of undergoing apop-
tosis if stimulated appropriately or hit hard enough.
Where do Bcl-2 and its homologs ¢t into this story
of mitochondrial PT pore opening and release of
caspase activating proteins? Several groups have
now reported that over-expression of Bcl-2 or similar
cytoprotective members of the Bcl-2 family such as
Bcl-XL confers protection upon mitochondria, mak-
ing it more di⁄cult for many stimuli to induce PT
pore opening and release of AIF and cytochrome c
[42^44,50,51]. Conversely, over-expression of the
pro-apoptotic protein Bax has been demonstrated
to induce loss of v8 and release of cytochrome c
[52^54]. The mechanisms by which Bcl-2 prevents
and Bax promotes these destructive changes in mito-
chondria, however, are far from clear.
It has been hypothesized that Bcl-2 family proteins
directly participate in regulation of the PT pore. In
support of this idea are experiments in which at-
tempts were made to purify the multiprotein PT
pore complex from mitochondria and reconstitute it
in synthetic liposomes. During puri¢cation of the PT
complex, Bax was reportedly co-puri¢ed, resulting in
an approx. 50-fold enrichment of this protein and
implying that Bax may be closely associated with
proteins that constitute components of the PT pore
[55]. Moreover, the partially puri¢ed PT pore com-
plex retained many of its expected functional charac-
teristics when reconstituted in liposomes, including
suppression of pore opening by recombinant Bcl-2
protein but not by mutants of Bcl-2 which fail to
suppress apoptosis in intact cells [55,56].
Some other observations, however, have suggested
the possibility that Bcl-2 family proteins perform
other functions in mitochondria which are perhaps
only indirectly related to PT pore regulation. For
example, comparisons of the time courses of cyto-
chrome c release and mitochondrial v8 loss in cells
undergoing apoptosis caused by growth factor dep-
rivation or cytotoxic anticancer drugs have provided
evidence that cytochrome c release can precede v8
loss in at least some types of cells [42,43,57]. In this
scenario, it has been argued that only a portion of
the total available cytochrome c needs to be released
into the cytosol to result in caspase activation
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[54,58]. The idea is that su⁄cient cytochrome c re-
mains inside mitochondria, bound to cytochrome c
oxidase for handling electron transport from com-
plex III to IV in the respiratory chain, so that respi-
ration is unimpaired and v8 is maintained.
If true, then how does a protein the size of cyto-
chrome c (approx. 12 kDa) transit from its normal
place of residence in the intermembrane space across
the outer membrane into the cytosol? One idea that
has been proposed recently is that mitochondrial vol-
ume dysregulation with matrix swelling and outer
membrane rupture can occur independent of PT
pore opening, perhaps as a result of changes in the
function of some of the various ion transporters
found in the inner membrane [58]. Alternatively, it
could be that pores are created de novo in the outer
membrane that allow some of the cytochrome c to
escape, while leaving the permeability of the inner
membrane intact. In support of the latter, it has re-
cently been shown that addition of recombinant Bax
protein to isolated mitochondria can induce release
of cytochrome c without attendant swelling of mito-
chondria, suggesting that PT pore opening is not
necessarily required for escape of cytochrome c
[54]. Moreover, evidence has been obtained suggest-
ing that in some circumstances where cytochrome c
release appears to precede PT pore opening, caspase
activation may be required for the loss of v8 but not
for the release of cytochrome c [57]. In this regard,
certain caspases have been reported to induce PT
pore opening when applied to isolated mitochondria
in vitro [46,55]. Taken together, therefore, these ob-
Fig. 1. Potential mechanisms of cytochrome c release from mitochondria. Available data suggest the existence of two principal path-
ways for release of cytochrome c : one in which the organelles swell and the outer membrane ruptures (top) and another in which the
outer membrane remains largely intact but the permeability changes su⁄ciently to allow transit of cytochrome c (bottom). Depending
on the stimulus for cell death, either pathway may predominate, but because active caspases can also induce mitochondrial PT pore
opening [46,55], the opportunity for feedward loops exists in which release of cytochrome c through pathways that do not entail loss
of v8 and outer membrane rupture can recruit additional mitochondria through caspase-dependent mechanisms that do involve loss
of v8 and organellar swelling. It has been suggested that the pathway resulting in swelling and outer membrane rupture may occur
either as a result of PT pore opening which is accompanied by loss of v8 [39,104] or through alternative mechanisms in which the in-
ner membrane is largely intact and v8 is maintained [58]. The release of cytochrome c from mitochondria is caspase-independent, im-
plying that this event is upstream from caspase activation at least in cell death scenarios where mitochondria play roles as initiators
of apoptosis [54]. The induction of PT pore opening, as de¢ned by loss of v8, however, may take place either upstream or down-
stream from caspase activation.
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servations imply the existence of a feed-forward
mechanism by which cytochrome c release from a
few mitochondria can induce mitochondrial PT
pore opening, resulting in release of more cyto-
chrome c and possibly other caspase activators
such as AIF from mitochondria (Fig. 1).
3. Location, location, location
In the Real Estate business, location is everything.
Is the intracellular location critical for the function
of Bcl-2 family proteins? Though the mitochondrial
location is typically emphasized, signi¢cant portions
of the Bcl-2 protein are also integrated into the mem-
branes of the endoplasmic reticulum (ER) and nu-
clear envelope [33^36]. Moreover, some members of
the Bcl-2 family such as Mcl-1, Bak, and E1b-19kDa
may be located preferentially if not exclusively in
non-mitochondrial sites ([59,60]; R. Brown, personal
communication). Attempts have been made to an-
swer the question of whether association of Bcl-2
with mitochondria is absolutely required for its
anti-apoptotic function through mutational analysis
of this protein and a closely related homolog Bcl-XL.
When the carboxyl approx. 20 amino acids constitut-
ing the membrane-anchoring domain is deleted from
Bcl-2 or Bcl-XL, much of the protein is found in a
soluble cytosolic fraction and cytoprotective function
is often reduced but not completely abrogated [61].
In addition, an isoform of the Bcl-XL protein has
been described which arises through alternative
mRNA splicing mechanisms and that lacks the car-
boxyl transmembrane (TM) domain but which re-
mains functional as a suppressor of cell death [62].
However, perhaps due in part to its ability to dimer-
ize with endogenous Bcl-2 family proteins, substan-
tial proportions of the Bcl-2 (vTM) and Bcl-XL
(vTM) proteins are typically associated with mem-
branes [63], making it di⁄cult to interpret the signi¢-
cance of the ¢ndings.
Other experiments in which the carboxyl TM do-
main of Bcl-2 was substituted with analogous mem-
brane-anchoring domains from either an outer mito-
chondrial protein or a type II ER membrane protein
revealed that ER-targeted Bcl-2 was markedly im-
paired in its ability to protect against apoptosis in-
duced by several stimuli, whereas mitochondria-tar-
geted Bcl-2 was essentially as potent as the wild-type
protein [64]. These observations support view that
the major cytoprotective function of Bcl-2 is related
to its e¡ects on mitochondria. Nevertheless, ER-tar-
geted Bcl-2 retained the ability to block apoptosis
induced by serum deprivation from Myc-expressing
cells, suggesting that Bcl-2 does indeed possess some
non-mitochondrial mechanisms for promoting cell
survival [64]. In this regard, Bcl-2 has also been re-
ported to regulate Ca2 homeostasis in the ER,
where it evidently prevents or delays pathological
leakage of Ca2 from this organelle under some cir-
cumstances [65^68]. Moreover, Bcl-2 has been re-
ported to bind two ER membrane proteins, Bap31
and BI-1, which participate in apoptosis regulation
through unde¢ned mechanisms [69,70].
In addition, Bcl-2 has been localized to the nuclear
envelope and immunoelectron microscopic studies
suggest potential association with nuclear pore com-
plexes [32,34]. In some types of cells, over-expression
of Bcl-2 prevents translocation of the apoptosis-in-
ducing protein p53 from cytosol into nucleus [71,72],
suggesting that Bcl-2 may snag selected proteins as
they try to transit through nuclear pore complexes.
Taken together, therefore, it seems that Bcl-2’s ac-
tions in cells are not relegated solely to protecting
mitochondria during cellular confrontation with
apoptosis-inducing insults and stimuli. Though mito-
chondria may be a major site of action of the Bcl-2
family proteins, clearly under some speci¢c circum-
stances Bcl-2 can suppress potentially cytodestructive
events at other locations.
4. Multi-functional Bcl-2 family proteins
Though a clear understanding of how Bcl-2 and its
homologous proteins regulate cell life and death re-
mains elusive, currently available data suggest that
some members of this protein family are multifunc-
tional, possessing more than one mechanism for
modulating cell death (reviewed in [73]). Three gen-
eral types of functions have been recognized: (a) di-
merization with other Bcl-2 family proteins; (b) pore
or ion channel activity; and (c) binding to non-ho-
mologous proteins. The dimerization among various
members of the Bcl-2 family and its functional con-
sequences will not be discussed here in detail.
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5. Pore/channel formation
The ¢rst suspicion that some Bcl-2 family proteins
might be capable of forming pores or ion channels in
membranes came with the determination of the
three-dimensional structure of Bcl-XL [74]. The
Bcl-XL protein is comprised of seven K-helices joined
by £exible loops, and shares striking similarity to the
pore forming domains of some types of bacterial
toxins, e.g., diphtheria toxin (DT) and the colicins.
Molecular modeling studies suggest that anti-apop-
totic proteins such as Bcl-2 and some types of pro-
apoptotic proteins such as Bax share the same fold
with Bcl-XL [75]. As predicted by their structures,
Bcl-2, Bcl-XL and Bax have all been shown to
form ion channels at least in vitro when added to
synthetic membranes under conditions previously
shown to be conducive for channel formation by
DT and the bacterial colicins [76^79]. However, the
relative conductances, ion selectivities and dynamic
characteristics of these channels appear to di¡er.
Though far more work needs to be done, the general
suggestion is that the cytoprotective proteins Bcl-2
and Bcl-XL tend to form small channels that assume
a mostly closed conformation, preferring cations,
whereas the pro-apoptotic protein Bax tends to
form larger channels, which assume a mostly open
conformation and prefer anions (reviewed in [75]).
Moreover, evidence has been obtained that under
some in vitro conditions, Bcl-2 may be able to pre-
vent channel formation by Bax [78], suggesting a
potential mechanism for the antagonism displayed
between these proteins.
How might channel forming activity explain the
e¡ects of Bcl-2 family proteins on mitochondria?
Probably the simplest theory is that pro-apoptotic
proteins such as Bax form large channels in the outer
membrane of mitochondria which liberate cyto-
chrome c. Though K-helical proteins in general
form relatively small channels, diphtheria toxin
is believed to create pores large enough to allow
a polypeptide, namely the A-subunit of the toxin
(ADP ribosylation factor), to escape the endo-
somal/lysosomal compartment and enter the cytosol
where it inhibits translation and causes cell death
[80]. Thus, precedence exists for protein transport
by other pore-forming proteins which are predicted
to share structural similarity with Bax. Indeed,
the recent observation that recombinant Bax protein
can induce speci¢c release of cytochrome c from
isolated mitochondria without attendant mitochon-
drial swelling lends support to this idea [54]. How-
ever, it still remains to be determined whether Bax
directly forms pores in the outer membrane of su⁄-
cient size to liberate the approx. 12 kDa cytochrome
c protein.
More di⁄cult to envision is how a small conduc-
tance ion channel created in the outer membrane by
Bcl-2 or Bcl-XL could impact mitochondrial physi-
ology, given that the outer membrane is presently
believed to be rather porous due to the presence of
VDAC. Even in its ‘closed’ conformation, this L-bar-
rel-type channel protein creates pores of estimated
1.5 nm diameter [81]. Thus, the outer membrane
should be freely permeable to ions and most metab-
olites. One possibility is that Bcl-2 and Bcl-XL func-
tionally communicate with inner membrane proteins
that govern ion transport. These proteins could in-
clude components of the PT pore as suggested above
[39,55,82], or ion transporting proteins that control
volume regulation of the matrix space as implied by
one recent report [58]. It has also been suggested that
Bcl-2 and Bcl-XL somehow regulate the pH of the
intermembrane space, reportedly causing increased
rates of extrusion of protons from mitochondria
[83]. Again, since pH regulation in mitochondria is
governed by inner membrane transporters, this ob-
servation implies a mechanism for functional com-
munication between Bcl-2 family proteins in the out-
er membrane and H channels in the inner
membrane. Alternatively, perhaps a small portion
of the total mitochondria-associated pool of Bcl-2,
Bcl-XL, or Bax protein is actually located in the in-
ner membrane [84], an idea that deserves further
scrutiny. Finally, though a heretical notion, it has
also been argued by some that the outer membrane
of mitochondria is not freely permeable to protons,
prompting speculations that pore-forming Bcl-2 fam-
ily proteins have a role to play as transporters of H
within the outer membrane [58]. The suspicion is that
controlling proton transport across the outer mem-
brane would contribute to v8 regulation by either
increasing or decreasing the pH of the intermem-
brane space, and this in turn could translate some-
how into either resistance or susceptibility to cell
death stimuli.
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Regardless of the mechanisms involved, studies of
the e¡ects of ectopic expression of human Bcl-2 fam-
ily proteins in yeast have provided further indirect
support for the hypothesis that at least some of these
cell death-regulatory proteins may be capable of
forming channels in membranes and have demon-
strated evolutionary conservation of at least some
aspects of the function of these proteins. For exam-
ple, expression of the pro-apoptotic proteins Bax and
Bak in either budding or ¢ssion yeast induces cell
death, which can be prevented by co-expression of
anti-apoptotic proteins such as Bcl-2 and Bcl-XL
[30,85^88]. In contrast, deletion mutants of Bax
and Bak that lack the putative pore-forming K5-
and K6-helices are inactive when expressed in yeast
([87] and unpublished observations). Since yeast con-
tain no recognizable Bcl-2 homologs, it is unlikely
that Bax and Bak kill yeast by dimerizing and inter-
fering with the functions of such proteins in yeast. In
support of this argument, single amino acid substi-
tution mutants of Bax have been described which fail
to dimerize with Bcl-2 or Bcl-XL and yet retain their
lethality in yeast as well as mammalian cells [89].
Moreover, Bcl-2 can still rescue both yeast and mam-
malian cells from death induced by dimerization-de-
fective mutants of Bax, implying that Bcl-2 possesses
intrinsic cytoprotective functions which can manifest
themselves independent of heterodimerization with
Bax. In addition, pro-apoptotic Bcl-2 family proteins
such as Bcl-XS and Bik, which are not predicted to
share the same structural fold with the pore-forming
members of the family, fail to confer a lethal pheno-
type in yeast [30,87,88]. It has been speculated that
these proteins like Bcl-XS and Bik are limited to
counteracting the e¡ects of Bcl-2, Bcl-XL, and other
anti-apoptotic Bcl-2 family proteins with which they
dimerize, lacking an intrinsic function as channel
proteins, and thus have no phenotype when ex-
pressed in yeast [89]. While far more work needs to
be done, the data available to date therefore strongly
suggest that the phenotypes of certain Bcl-2 family
proteins in yeast are a re£ection of their ability to
form channels in intracellular membranes. However,
detailed mutagenesis experiments are needed to con-
¢rm this hypothesis by altering speci¢c residues with-
in the putative pore-forming K-helices of these pro-
teins and correlating changes in their channel
characteristics in vitro with their functions in yeast.
Where do mitochondria ¢gure in the explanation
for the cell death phenotype exhibited by certain Bcl-
2 family proteins in yeast? When expressed in the
budding yeast Saccharomyces cerevisiae, Bax is re-
portedly targeted to mitochondria. Deletion of the
C-terminal TM domain from Bax results instead in
a mostly cytosolic location of the protein and loss of
its cytotoxic function in yeast [89], similar to the
situation seen in some types of mammalian cells
where Bax (vTM) truncation mutants have been
studied [90]. Mitochondrial targeting and lethal func-
tion of Bax (vTM) can be restored in yeast by creat-
ing chimeric fusion protein which append the mem-
brane-anchoring domain of the yeast outer
mitochondrial membrane protein Mas70p to Bax
(vTM), implying that integration of Bax into mito-
chondrial membranes is critical for its cell death-in-
ducing activity in yeast. However, since no attempts
have been made to force targeting of Bax to other
organelles, it cannot necessarily be concluded that
Bax’s only site of action in yeast is mitochondria.
Nevertheless, ectopic expression of Bax in S. cerevi-
siae has been reported to induce release of cyto-
chrome c into the cytosol [91], paralleling the result
obtained in mammalian cells where Bax has also
been shown to induce cytochrome c release from
mitochondria [52,54]. Furthermore, genetic analysis
of yeast resulted in the discovery that certain sub-
units of the FoF1ATPase/proton pump of the inner
membrane are required for Bax-induced death, thus
further strengthening the functional connections be-
tween mitochondria and Bax [92]. Interestingly, a
functional FoF1-ATPase/proton pump appears to
also be required for optimal killing of mammalian
cells by Bax, based on experiments where oligomycin
was used to prevent H transport by FoF1, resulting
in reductions in Bax-induced apoptosis [92]. Why the
FoF1-ATPase/proton pump is required for the cyto-
toxic activity of Bax is presently unknown, but pos-
sibilities include: (a) necessity of FoF1 for creating
conditions of local pH that are conducive for channel
formation by Bax; and (b) use of FoF1 as an e¡ector
of Bax-induced cell death, perhaps by running the
pump ‘backwards’ so that protons are extruded
from the matrix at the expense of ATP hydrolysis
rather than the normal situation where protons
£ow down their concentration gradient from the in-
termembrane space into the matrix and ATP is gen-
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erated. Alternatively, the FoF1-ATPase/proton
pump may not be required for Bax-induced cell
death, but its absence may have protective e¡ects.
For example, in the absence of the proton pump,
less utilization of the proton gradient would occur
and hence the vpH should be higher (i.e. lower pH
in the intermembrane space). Perhaps this more
acidic environment within the local space between
the inner and outer membranes somehow precludes
Bax from performing its functions. Interestingly, it
has recently been suggested that Bcl-2 can increase
the extrusion of protons through a mechanism that
does not involve increased oxygen consumption [83].
If this enhanced extrusion of protons from the ma-
trix of mitochondria is related to the mechanism by
which Bcl-2 provides cytoprotection, then loss of the
FoF1-ATPase/proton pump theoretically would
mimic the actions of Bcl-2 by decreasing the local
pH of the intermembrane space. Again, how this
a¡ects the state of Bax in the outer membrane re-
mains unclear, but perhaps outer membrane proteins
can be in£uenced by the local pH of the intermem-
brane space, particularly at the contact sites where
the inner and outer membranes come into close ap-
position. Though loss of FoF1 may functionally
mimic Bcl-2, circumstantial evidence suggests that
Bcl-2 does not function by inhibiting FoF1 [83].
Bcl-2 also does not increase oxygen consumption or
a¡ect mitochondrial ATP levels, implying that it
does not use the respiratory chain (complexes I,
III, IV) to increase proton extrusion. Indeed, Bcl-2
can still protect from apoptosis under anaerobic con-
ditions [93,94] and retains its activity in cells that are
defective in oxidative phosphorylation due to a lack
mitochondrial DNA [95].
Which of the e¡ects of Bax on mitochondria is
actually responsible for cell death? Bax induces cy-
tochrome c release from mitochondria but yeast have
no detectable caspases and fail to undergo apoptosis,
as de¢ned by morphological criteria. Thus, cyto-
chrome c-mediated activation of cell death proteases
seems an unlikely explanation. However, if cyto-
chrome c loss from mitochondria reaches the point
that electron transport halts, then clearly mitochon-
drial ATP synthesis would cease and electrons de-
rived from NADH would likely be shunted into
free radical generation, resulting in direct damage
to membranes and macromolecules. The idea has
therefore arisen that cytochrome c release from mi-
tochondria has two ways of potentially killing cells :
one involving caspase activation (at least in animal
cells) and another resulting from the failure of elec-
tron chain transport in the inner membrane when
cytochrome c becomes limiting (which presumably
applies to both yeast and animal cells). In this re-
gard, in mammalian cells, over-expression of Bax
normally leads to v8 loss, cytochrome c release, cas-
pase activation and apoptosis. However, if agents are
employed to block caspases, then Bax still induces
v8 loss and cytochrome c release but instead of
apoptosis a necrosis-like cell death process ensues
which (by electron microscopic analysis) shares re-
markable ultrastructural similarity with Bax-medi-
ated cell death in yeast [53,86^88]. These and other
observations have provided evidence that ‘commit-
ment’ to cell death can be regulated at a point up-
stream from caspases, at least when mitochondria
play a pivotal role in the mechanism.
6. Pore-independent e¡ects of Bcl-2 family proteins
on mitochondria
In addition to forming channels in membranes,
Bcl-2 or some of its anti-apoptotic homologs such
as Bcl-XL can bind to several proteins located either
in the cytosol or in intracellular membranes (re-
viewed in [73]). Perhaps the most interesting of these
is Apaf-1, the cytosolic protein which cytochrome c
uses to activate caspases. Apaf-1 contains an N-ter-
minal domain that binds to caspase-9, and another
domain that binds to Bcl-XL which is homologous
to the nematode (C. elegans) death protein CED-4
[48,96]. Though no ¢rm evidence yet exists that Bcl-
XL can suppress the function of Apaf-1, studies of
the analogous proteins in C. elegans have revealed
that the Bcl-2/Bcl-XL homolog CED-9 can inhibit
CED-4, preventing it from activating the caspase
CED-3 [97,98]. Moreover, under some circumstan-
ces, it appears that Bcl-2 can suppress apoptosis in-
duced by microinjection of cytochrome c, implying
that it might interfere with Apaf-1. However, since
this is not uniformly seen, cell context-dependent fac-
tors must in£uence whether Bcl-2 can suppress cell
death downstream from cytochrome c [99,100].
By sitting in the outer membrane of mitochondria
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oriented towards the cytosol, Bcl-2 is able to recruit
cytosolic proteins with which it interacts to the mi-
tochondrial surface. Examples of this phenomenon
include the protein kinase Raf-1 and the phosphatase
calcineurin, both of which can be co-immunoprecipi-
tated with Bcl-2 and which are targeted from the
cytosol to the organellar sites where Bcl-2 resides
when Bcl-2 is over-expressed in cells [101,102]. A
regulator of Hsp70/Hsc70 family molecular chaper-
ones, BAG-1, can also be targeted to the surface of
mitochondria through interactions with Bcl-2 [103].
This situation may create opportunities for Bcl-2 to
bring signal transducing enzymes and chaperones
into contact with mitochondrial proteins that they
would not otherwise meet in cells. However, to
date, the only recognized targets of such Bcl-2 inter-
acting proteins are either Bcl-2 itself or other Bcl-2
family proteins. Interestingly, no known examples of
Bax or other pro-apoptotic Bcl-2 family proteins
binding to non-homologous proteins exist, implying
a key functional di¡erence between the death block-
ers and the death inducers. However, the dimeriza-
tion of Bcl-2 or Bcl-XL with Bax or other pro-apop-
totic Bcl-2 family proteins disrupts their interactions
with proteins such as Apaf-1 and calcineurin
[96,102], suggesting a mechanism by which proteins
such as Bax, Bak, Bik, and BAD may antagonize the
function of Bcl-2, Bcl-XL, and their anti-apoptotic
homologs.
7. Summary
Though many details about mechanisms are lack-
ing, it has become abundantly clear that Bcl-2 family
proteins exert profound e¡ects on mitochondria. The
structural homology of some Bcl-2 family proteins to
the pore forming domains of bacterial toxins raises
the possibility that these molecules may act as chan-
nels for either ion or protein transport across the
membranes of mitochondria. Mitochondria, long im-
plicated in necrotic cell death through generation of
reactive oxygen species during ischemia reperfusion
injury, have now been tied to caspase activation and
apoptosis through their ability to release proteins
that trigger the cell death proteases into action.
The intimate relation that mitochondria share with
cell death stands in sharp contrast to the role that
these organelles play as the engines of ATP produc-
tion and sustainers of cell life. This dual role of mi-
tochondria has served animal species well over evo-
lution, but also creates opportunities for
dysregulation that contributes to human diseases.
Greater understanding of all facets of these complex
organelles is needed if we are to ultimately tame their
pathological tendencies in diseases characterized by
inappropriate cell death such as myocardial infarc-
tion, stroke, AIDS, and neurodegeneration, or har-
ness it for good purposes in disorders caused by in-
su⁄cient cell death such as cancer, autoimmunity,
and restenosis.
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